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Summary
The effects of fluvastatin, a synthetic hydroxymethylglutaryl coen-
zyme A (HMG-CoA) inhibitor, on the biosynthesis of tissue plasmino-
gen activator (t-PA) and of its major physiological inhibitor (plasmino-
gen activator inhibitor type 1, PAI-1) were investigated in cultured 
human umbilical vein endothelial cells (HUVEC). Fluvastatin (0.1 to
2.5 M), concentration-dependently reduced the release of PAI-1 
antigen by unstimulated HUVEC, subsequent to a reduction in PAI-1
steady-state mRNA levels and de novo protein synthesis. In contrast, it
increased t-PA secretion.
The drug also reduced PAI-1 antigen secreted in response to 
10 g/ml bacterial lipopolysaccharide (LPS), 100 U/ml tumour necro-
sis factor  (TNF) or 0.1 M phorbol myristate acetate (PMA).
Mevalonate (100 M), a precursor of isoprenoids, added to cells 
simultaneously with fluvastatin, suppressed the effect of the drug on
PAI-1 both in unstimulated and stimulated cells as well as on t-PA 
antigen. Among intermediates of the isoprenoid pathway, all-trans-
geranylgeraniol (5 M) but not farnesol (10 M) prevented the effect
of 2.5 M fluvastatin on PAI-1 antigen, which suggests that the former
intermediate of the isoprenoid synthesis is responsible for the observed
effects. 
Introduction
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)
reductase (statins) are competitive inhibitors of cholesterol synthesis by
blocking the conversion of HMG-CoA to mevalonate, the rate-limiting
step in cholesterol biosynthesis. Besides their efficacy in the treatment
of hypercholesterolemia, these drugs have been shown to reduce car-
diovascular mortality and morbidity (1–3). However, the observation
that the benefit in terms of cardiovascular and cerebrovascular events is
partly independent of baseline lipid levels (4, 5), suggests that choleste-
rol-independent mechanisms may be responsible for these effects.
Moreover, the reductions in atherosclerotic plaque progression as well
as in intimal-medial thickness of carotid arteries induced by statins are
small in size and do not fully account for the beneficial effects of these
drugs (6–7). Arterial plaque stabilization as well as changes in their
proinflammatory content has been proposed as potential mechanisms
(8, 9). In addition statins have been shown to have antithrombotic 
effects (8, 10). They reduce in vivo platelet activation (11) and platelet
deposition on mildly damaged vessel walls (12), prevent endothelial
dysfunction (13–15) as well as macrophage tissue factor expression
(16).
Vascular thrombosis results from a complex interaction between
vessel wall and blood constituents, which leads to fibrin deposition.
The lysis of fibrin deposits within the vascular tree is brought about by
plasmin, which binds to fibrin-rich thrombi and gives rise to fibrin de-
gradation products. The generation of plasmin within the circulation is
regulated by tissue plasminogen activator (t-PA) and by its major 
inhibitor, tissue plasminogen activator inhibitor type 1 (PAI-1) (17).
Elevated levels of PAI-1 in plasma have been shown to be predictive of
cardiovascular events in free-living populations and in survivors of
myocardial infarction (17–20). Clinical data on the effects of statins on
plasma fibrinolytic parameters are still conflicting (10).
Recently it has been shown that the HMG-CoA reductase inhibitors
lovastatin and simvastatin in vitro increase t-PA mRNA expression and
reduce PAI-1, thereby favouring fibrinolysis in endothelial cells (21). 
Fluvastatin ([R,S-(E)]-(±)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-
1H-indole-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt) is a
synthetic HMG-CoA reductase inhibitor that has been shown to effec-
tively reduce plasma total and LDL cholesterol levels (22). In this 
study we have investigated the effects of this drug on the biosynthesis
of PAI-1 antigen by cultured human umbilical vein endothelial cells
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sis factor  (TNF), aprotinin, farnesol and mevalonate (as mevalonolactone)
were from Sigma Chemical Co. Protein-A Sepharose was from Pharmacia Fine
Chemical. LPS (Escherichia coli 011:B4) was obtained from Difco Labs. 
Fluvastatin as sodium salt (Novartis, Basel, Switzerland) was dissolved in 
ethanol immediately before use.
Cell Culture
Human umbilical vein endothelial cells (HUVEC) were obtained from um-
bilical cord using the method of Jaffe (23) and grown to confluence in 25 cm2
tissue culture flasks (Costar, Cambridge, Mass.). The cells were cultured in 
medium 199 (M199) containing 20% fetal calf serum (FCS), 2 mM L-gluta-
mine, 50 UI/ml penicillin, 50 g/ml streptomycin, 0.1 mg/ml of porcine 
intestinal heparin and 0.1 mg/ml crude extract of endothelial cell growth factor
(ECGF). The cells used in these studies were between the first and second 
passages and had been derived from single cords. 
Experimental Procedures
Confluent cells were split 1:1 into 12 well cluster plates (4 cm2) and grown
until confluency. Cells were then incubated for 24 h in M199 containing 15%
FCS, heparin 0.1 mg/ml, ECGF 0.1 mg/ml and different concentrations of 
fluvastatin (0–2.5 M). Mevalonate and isoprenoids were present through the
incubation where indicated. The cells were then exposed for 16 h to freshly pre-
pared medium containing 2.5% FCS, in the presence of fluvastatin (0–2.5 M)
and/or mevalonate and isoprenoids and an appropriate stimulus: LPS 
(10 g/ml), PMA (0.1 M) or TNF (100 U/ml). After incubation the condi-
tioned medium (CM) was collected and centrifuged to remove cell debris and
stored at –20° C.
Quantitation of t-PA and PAI-1 Antigen 
PAI-1 and t-PA antigen were measured by means of a commercial ELISA
kit (FI-5 Monozyme, Copenhagen, Denmark for PAI-1 and Imulyse, Biopool
AB, Umea, Sweden for t-PA) in accordance with the manufacturer’s instruc-
tions. Data were expressed as ng antigen/g cell protein by comparison with a
standard curve. Total protein concentrations of cell lysates were determined by
the Bradford method (24).
Quantitation of t-PA Activity
t-PA activity was determined in conditioned medium by a chromogenic
plasmin substrate assay. Different amounts of CM were incubated in a 96-well
microtest plate in the presence of pPAR/L (Biopool, Sweden), a reaction mix-
ture containing Glu-plasminogen, poly-D-lysine and a chromogenic substrate
for plasmin (D-But-CHT-Lys-pNA). Absorbance was measured at 405 nm, in a
spectrophotometric plate reader, after overnight incubation at 37° C. Data were
expressed as International Unit of t-PA in comparison with a curve of standard
t-PA run in parallel.
RNA Isolation and Northern Blot Analysis
Total cellular RNA was obtained from cells seeded in a 25 cm2 flask accord-
ing to Chomczynski (25). 10–20g of total RNA, determined spectrophoto-
metrically, was subjected to electrophoresis in formaldehyde-agarose gel and
transferred overnight to nylon membranes (Hybond N, Amersham). Mem-
branes were prehybridized (4 h) and hybridized overnight at 42°C, in 50% for-
mamide, SSPE 5 (0.75 mol/L NaCl, 0.05 mol/L NaH2PO4·H20, 5 mmol/L
EDTA), Denhardt’s solution 4, salmon-sperm DNA 100 g/ml and bakers
yeast t-RNA 200 g/ml. Hybridization was performed with human cDNA 
PAI-1 or t-PA and human cDNA GAPDH labeled with 32P d-CTP by the 
random primer method, as described by the manufacturer (Rediprime DNA 
labelling system, Amersham). Membranes were then washed under stringently
controlled conditions at 42° C (two washes with 5SSPE, one wash with 
1SSPE, 0.1% SDS and one with 0.1SSPE, 0.1% SDS). Filters were 
air-dried and exposed to autoradiography film (Hyperfilm MP, Amersham)
with intensifying screens at – 80° C. Autoradiography bands were quantified
(density  area) using the NIH Image and results expressed in arbitrary units.
Labeling of HUVEC with [35S]-methionine
Endothelial cells were preincubated for 24 h with the appropriate com-
pounds in M199 containing 15% FCS, 0.1 mg/ml of heparin and ECGF. After
three washings with medium alone, cells were then incubated in methionine-
free Minimum Essential Medium (MEM) in the presence of 20 Ci/well 
[35S]-methionine (350 Mbq/ml, Amersham), containing 2.5% FCS, 0.1 mg/ml
heparin, 0.1 mg/ml ECGF, and the appropriate compounds or stimulus. At the
end of the incubation, CM was collected and centrifuged at 10,000 g for 5 min
to remove cell debris. Cells were washed three times with PBS and extracted in
500 l of PBS pH 8.0, containing 0.5% Triton X-100, for 5 min at 37° C. 
The extra cellular matrix was then washed extensively with bidistilled water
Fig. 1 Effect of fluvastatin on PAI-1 secretion by HUVEC. Monolayers of
confluent HUVEC were preincubated for 24 h with fluvastatin (0-2.5 M) or
vehicle in Medium 199 containing 0.1 mg/ml heparin, 0.1 mg/ml ECGF, 15%
FCS. The medium was then removed and cells were exposed for 16 h to fresh-
ly prepared medium containing 2.5% FCS in the presence of the same concen-
trations of fluvastatin or vehicle. PAI-1 antigen levels were determined in the
conditioned medium as described in “Methods”. Results are expressed as mean
percentages of vehicle treated cells taken as control (100%). Data are given as
arithmetic means (with vertical lines showing SEM of five individual experi-
ments performed in duplicate)
Fig. 2 Effect of mevalonate (M), all-trans-geranylgeraniol (GG) and farnesol
(Far) on PAI-1 secretion exerted by fluvastatin (F). Cells were exposed to F 
(2.5 M) and the different isoprenoids (M 100 M; GG 5 M; Far 10 M) 
for preincubation and incubation times (24 + 16 h) as specified in legend to 
figure 1. Data represent percent of vehicle treated cells and are given as 
arithmetic means (with vertical lines showing SEM of 7 individual experiments
performed in duplicate). ** p <0.01 versus vehicle treated cells (C)
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and removed with 500 l PBS containing 0.1% SDS. The absence of cells and
cell debris in extra cellular matrix was verified by light microscopy. Samples
divided into aliquots were stored at –70° C until use.
Immunoprecipitation of PAI-1
Immunoprecipitation was performed, after metabolic labeling of cells with
[35S] methionine, as previously described (26) with slight modifications as 
follows. Radiolabeled conditioned medium (100 l), cell extracts (25 l) or 
extracellular matrix (10 l) were incubated with 15 g goat polyclonal anti-
body against human PAI-1 (Product 379 American Diagnostica Inc.) or with 
15 g goat nonimmune IgG for 16 h at 4° C in the presence of PMSF (1 mM).
Immune complexes were conjugated to Protein-A Sepharose suspension (50 l
of packed beads) for 1 h at 4° C. Beads were precipitated at 10,000g for 15 min,
washed 3 times with PBS pH 7.4 containing 1 mM PMSF, 100 IU/ml aprotinin,
0.1% SDS, 0.1% Nonidet P-40 and twice with cold PBS. Immunoprecipitated
proteins were solubilized in 55 l of Laemmli sample buffer (27), heated to
100° C for 3 min and subjected to SDS-PAGE (12% acrylamide) under redu-
cing condition. After electrophoresis, gels were fixed and subjected to auto-
radiography on Hyperfilm-MP (Amersham) at –80° C.
Statistical Analysis 
All experiments were conducted in duplicate with individual preparations 
of HUVECs. The results are expressed as mean ± SEM. Comparisons among
treatment conditions were carried by two-tail variance analysis followed by
Dunnett’s test. The accepted level of significance was p < 0.05.
Results
Effect of Fluvastatin on PAI-1 Synthesis by Unstimulated HUVEC
Monolayers of confluent HUVEC were incubated for periods 
ranging from 3 to 24 h with the appropriate concentration of fluvastatin
or vehicle and then cultured for 16 h with freshly prepared media con-
taining 2.5% FCS and supplemented with the statin or vehicle alone. 
Fluvastatin (2.5 M) reduced PAI-1 antigen secretion in conditioned
medium and this effect was dependent upon the time of preincubation,
there being almost complete suppression at 24 h (data not shown). The
experiments described below were then performed in cells preincu-
bated with the drug for 24 h.
Fluvastatin, concentration-dependently, reduced the amounts of
PAI-1 by the cells from 1.69 ± 0.21 ng PAI-1 antigen/g protein 
(vehicle) to 1.45 ± 0.24, 0.4 ± 0.09 and 0.28 ± 0.09 ng PAI-1 anti-
gen/g protein, respectively at the concentration of 0.1, 1 and 2.5 M
(the IC50 being 0.34 M ± 0.037) (Fig. 1).
Mevalonate (100 M) added together with fluvastatin (2.5 M) 
fully prevented the effect of the drug on PAI-1 release, which indicates
that fluvastatin reduces PAI-1 release as a consequence of inhibition of
the HMG-CoA reductase enzyme (Fig. 2). Serum, a source of exoge-
nous cholesterol, was present during all incubations, thus, the possibil-
ity that the effect of fluvastatin on PAI-1 is due to depletion of intracel-
lular cholesterol can be ruled out. Therefore, intermediates of the me-
valonate pathway, other than cholesterol, are responsible for the ob-
served effects. Among the early derivatives of the isoprenoid pathway,
geranylgeraniol and farnesol are of particular importance in view of
Fig. 3 Effect of fluvastatin and geranylgeraniol on PAI-1 mRNA levels. Con-
fluent HUVEC were preincubated and then incubated with vehicle or fluvasta-
tin (2.5 M) and fluvastatin plus geranylgeraniol (5 M) as described in legend
to figure 1. Total RNA was extracted and analyzed by Northern blotting with
radiolabeled human-PAI-1 and human-GAPDH cDNA probes. A representa-
tive autoradiogram is shown. Lane 1: vehicle-treated cells; lane 2: fluvastatin-
treated cells; lane 3: cells treated with fluvastatin plus geranylgeraniol
Fig. 4 Effect of fluvastatin and geranylgeraniol on PAI-1 biosynthesis in con-
ditioned medium, intracellular and extracellular compartments. Confluent HU-
VEC, preincubated for 24 h with vehicle, fluvastatin (2.5 M) or fluvastatin
plus geranylgeraniol (5 M), and then incubated for further 16 h in methionine-
free MEM in the presence of 20 Ci/well [35S]-methionine (350 Mbq/ml,
Amersham). Labeled PAI-1 was detectable in a band of approximately 50 kD
in: (a) conditioned medium (100 µl) or (b) cell extracts (25 l) or (c) extracel-
lular matrix (10 l) after immunoprecipitation as described in “Methods”. 
Lane 1: vehicle-treated cells; lane 2: fluvastatin-treated cells; lane 3: cells 
treated with fluvastatin-plus geranylgeraniol
Fig. 5 Effect of fluvastatin, mevalonate and geranylgeraniol on PAI-1 release
in PMA-stimulated cells. Monolayers of HUVEC were incubated for 24 h with
fluvastatin (2.5 M) and the different isoprenoids (M 100 M; GG 5 M; Far
10 M), and for an additional 16 h with fresh medium containing fluvastatin,
isoprenoids and PMA (0.1 M). At the end of the incubation the medium was
removed and processed to measure PAI-1 antigen levels. Results are expressed
as mean percentages of vehicle treated cells taken as control (100%) and are
mean ± SEM of 6 experiments performed in duplicate. ** p < 0.01 versus
PMA-treated cells
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their role in the modifications of several proteins that regulate cell 
function. To determine whether the inhibition of PAI-1 biosynthesis 
induced by fluvastatin was mediated by depletion of isoprenoid inter-
mediates, all-trans-geranylgeraniol (5 M) and farnesol (10 M) were
added to HUVEC together with 2.5 M fluvastatin. Farnesol did not
modify the effect of fluvastatin on PAI-1 release, whereas all-trans-
geranylgeraniol completely prevented the inhibitory effect of fluvasta-
tin on PAI-1 secretion, which suggests a role of geranylgeranylated
proteins in PAI-1 regulation (Fig. 2). Northern blot analysis showed
that 2.5 M fluvastatin almost abolished the steady-state levels of both
the 3.2 and 2.2 kb PAI-1 mRNA transcripts compared with vehicle-
treated cells (Fig. 3), thus suggesting that fluvastatin inhibits PAI-1 pro-
tein synthesis as the result of inhibition of PAI-1 mRNA accumulation.
All-trans-geranylgeraniol (5 M) completely prevented the reduction
of PAI-1 mRNA exerted by fluvastatin, indicating that this effect is
consequent to the depletion of geranylgeraniol (Fig. 3).
Effect of Fluvastatin on the Biosynthesis of PAI-1 
in Unstimulated HUVEC
To determine whether changes in the accumulation of PAI-1 protein
in conditioned medium reflected changes in the rate of PAI-1 synthesis,
we performed metabolic labeling of HUVEC with [35S]-methionine.
Labeled PAI-1 was detectable in a band of approximately 50 kD that
was revealed in extracts obtained from conditioned medium, cells and
extracellular matrix. Fluvastatin (2.5 M) reduced the amount of [35S]-
PAI in the three compartments and all-trans-geranylgeraniol (5 M) re-
versed these effects (Fig. 4). Overall protein synthesis evaluated by
measuring the incorporation of TCA-precipitable [35S]-methionine into
cells and CM was not modified. In contrast it was reduced by 50% in
the extracellular matrix, in which the PAI-1 is the most abundant pro-
tein (28).
Effect of Fluvastatin on PAI-1 Release Induced by PMA, LPS and TNF
PMA, LPS and TNF drastically enhanced PAI-1 release in condi-
tioned medium of stimulated HUVEC (Figs. 5, 6) in accordance with
previous data (29). Fluvastatin (2.5 M) inhibited the release of PAI-1
induced by 0.1 M PMA and this inhibition was fully prevented by 
100 M mevalonate or 5 M all-trans-geranylgeraniol, but not by 
10 M farnesol (Fig. 5). Fluvastatin (2.5 M) inhibited PAI-1 secre-
tion in cells treated with LPS (10 g/ml) or TNF (100 U/ml) and 
10 M all-trans-geranylgeraniol restored it (Fig. 6).
Effect of Fluvastatin on t-PA Synthesis by Unstimulated HUVEC
In our experimental conditions HUVEC released relatively low
amounts of t-PA antigen within 16 h incubation (0.081 ± 0.006 ng/g
cell protein). HUVEC, however, incubated with media containing 
increasing amounts of fluvastatin (0.1-1-2.5 M) released greater 
amounts of t-PA antigen with a 70% increase at the 2.5 M con-
centration. This effect was reverted by mevalonate (Table 1). The 
fluvastatin-induced t-PA increases reflected the accumulation of steady
state levels of mRNA for t-PA, which was prevented by 100 M 
mevalonate (Fig. 7).
Fig. 6 Effect of fluvastatin and geranylgeraniol on PAI-1 secretion in untreat-
ed and LPS or TNF-treated cells. HUVEC were incubated for 24 h with flu-
vastatin (F) (2.5 M) and geranylgeraniol (GG) (5 M) and for an additional
16 h with fresh medium containing fluvastatin, geranylgeraniol and LPS 
(10 g/ml) (a) or TNF (100 U/ml) (b). At the end of the incubation time the
medium was removed and processed to measure PAI-1 antigen levels. Results
are expressed as mean percentages of vehicle treated cells taken as control
(100%) and are mean ± SEM of five (a) and three (b) experiments performed in
duplicate. ** p < 0.01 versus LPS-treated cells
Fig. 7 Effect of fluvastatin and mevalonate on t-PA mRNA levels. Confluent
HUVEC were preincubated and then incubated with vehicle or fluvastatin 
(2.5 M) and fluvastatin plus mevalonate (100 M) as described in Fig. 1. 
Total RNA was extracted and analyzed by Northern blotting with radiolabeled 
human-t-PA and human-GAPDH cDNA probes. A) Autoradiographic results:
lane 1, vehicle-treated cells; lane 2, fluvastatin-treated cells; lane 3, cells 
treated with fluvastatin plus mevalonate. B) Quantitative data obtained from 
the imaging screen expressed in arbitrary units
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t-PA activity in unstimulated HUVEC was below the sensitivity of
the assay (< 0.125 UI/ml) and was not influenced by fluvastatin (not
shown). In fact the increase in t-PA secretion induced by 2.5 M fluva-
statin did not exceed 0.055 ng/g cell protein, whereas the residual
PAI-1 antigen, after 2.5 M fluvastatin treatment, averaged 0.29 ng/g
cell protein, an amount grater than that of t-PA. 
Discussion
The plasminogen system plays an integral role in the regulation of
vascular physiology by regulating fibrinolysis and proteolysis of extra-
cellular matrix (30). Endothelial cells are central regulators of both 
systems determining the availability of both t-PA and PAI-1 (31). 
Increases in t-PA over PAI-1 thus favour fibrinolysis and proteolysis,
the opposite resulting in an impairment of both systems. The synthesis
and secretion of t-PA and PAI-1 by endothelial cells is highly regulated,
few agonists stimulate t-PA synthesis without affecting PAI-1 synthe-
sis (29, 32). Only a few drugs, however, have been shown to affect the
biosynthesis of these proteins. Fibric acid derivatives have been report-
ed to reduce, with various degrees of potency, PAI-1 transcription and
protein synthesis in HepG2 cells, with gemfibrozil as the most potent
and bezafibrate with minimal effects (33, 34). Gemfibrozil has also 
been shown to impair PAI-1 biosynthesis in endothelial cells (35). These
effects occur, however, only at very high concentrations (0.3-1 mM).
As for t-PA biosynthesis, only a few compounds have been shown to
influence it (32). Recently, lovastatin and simvastatin have been 
reported to increase fibrinolytic activity in the rat aortic endothelial cell
as the result of reduction in PAI-1 and increase in t-PA (21).
Data presented in this study show that fluvastatin, a synthetic 
HMG-CoA reductase inhibitor, improves endothelial cell function by
significantly reducing basal and stimulated PAI-1 biosynthesis and 
increasing t-PA secretion. Fluvastatin reduced PAI-1 mRNA steady
state levels, with an effect on both 2.2 and 3.2 kb transcripts, as well as
de novo synthesis of PAI-1 protein. In cultured cells > 97 % of PAI-1 is
secreted into the medium, 0.3% accumulates in the extracellular matrix
and 2.5–3% remains within the cells (data not shown). Fluvastatin 
reduced the amount of newly synthesized PAI-1 in the supernatant, cell
extracts and extracellular matrix, which indicates that the drug affects
the plasminogen system in both its fibrinolytic and proteolytic func-
tions. 
Fluvastatin not only reduced basal PAI-1 biosynthesis but also its 
increase as induced by a variety of agonists, the most pronounced 
effects being with PMA. The signalling pathways involved in PAI-1
biosynthesis were not addressed in this study. In this context, however,
it is worth mentioning that PAI-1 biosynthesis in endothelial cells 
induced by PMA or TNF recognizes a complex network of second
messengers ultimately involving protein kinase C activation and trans-
location (36).
Fluvastatin influenced also t-PA levels in conditioned medium of
unstimulated HUVEC, with a 70% increase at 2.5 M, and this effect
reflected an increase in t-PA steady-state mRNA levels. Simvastatin
and lovastatin, at similar concentrations, have been reported to increase
t-PA biosynthesis in Simian virus 40-transformed aortic endothelial
cell line (21), with an effect more marked than that observed in the 
present paper in fluvastatin-treated HUVEC. In contrast, no effect of
fluvastatin has been recently reported on t-PA antigen release by 
HUVEC incubated with medium containing 20% FCS (37).
The increase in t-PA antigen exerted by fluvastatin here described
did not result in appreciable changes in t-PA activity. This observation
can be explained by the fact that PAI-1 secretion by HUVEC far 
exceeds that of t-PA not only in basal condition but also after treatment
with fluvastatin and therefore the t-PA/PAI-1 molar ratio remains in 
favour of PAI-1 protein. 
All the effects of fluvastatin were prevented by mevalonate, the 
primary product of the HMG-CoA reductase enzyme, thus suggesting
that fluvastatin influence PAI-1 and t-PA through inhibition of the 
isoprenoid pathway. The effects of fluvastatin were not explained by
depletion of intracellular cholesterol, because experiments were per-
formed in the presence of 2.5% FCS, which provides an extracellular
source of cholesterol. Besides cholesterol, mevalonate is the precursor
of intermediates, which are substrates for prenylation of several pro-
teins. FPP is the precursor for farnesylation of proteins such as laminin
B and ras, whereas all-trans-GGPP is a substrate for geranylation of
other proteins, including many low molecular weight GTP-binding 
proteins (38, 39), that are involved in intracellular cell signaling. Inter-
estingly, all-trans-geranygeraniol mimicked the effects of mevalonate
in preventing the effects of fluvastatin on PAI-1. Thus, an effect of 
fluvastatin upstream of PAI-1 or t-PA gene transcription, via inter-
mediates of isoprenoids, can be hypothesized.
Lovastatin was shown to reduce PAI-1 biosynthesis as a result of the
inhibition of geranylgeranylated Rho proteins and of disruption of the
actin microfilaments in endothelial cells (21). A similar mechanism
may be involved with fluvastatin. On the basis of this study and on that
of Essig (21) it appears that the reduced availability of geranylgeraniol
influences the biosynthesis of t-PA and PAI-1 by HUVEC in opposite
directions. Thus, our data indicate that fluvastatin influences PAI-1 and
t-PA biosynthesis via inhibition of the HMG-CoA reductase enzyme
and that an intermediate of isoprenoid biosynthesis, e. g. geranylgera-
niol mediates this effect. 
In conclusion, this study demonstrates that fluvastatin, at concen-
trations readily achieved in vivo (22) influences endothelial cell func-
tion positively by effectively inhibiting PAI-1 and increasing t-PA
secretion.
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